NVO — NOVO NORDISK A S catalysts
Next verified catalyst
2026-08-21 — A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People Wit · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-08-21 in 15d
ESTIMATED |
READOUT
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in
Phase 2 · Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy |
NVO NOVO NORDISK A S | CagriSema (Cagrilintide B and Semaglutid |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-01 in 26d
ESTIMATED |
READOUT
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130
Phase 2 · Chronic Kidney Disease |
NVO NOVO NORDISK A S | NNC0519-0130, Semaglutide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-01 in 2mo
ESTIMATED |
READOUT
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Part
Phase 3 · Heart Failure, Systemic Inflammation |
NVO NOVO NORDISK A S | Ziltivekimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-12-14 in 4mo
ESTIMATED |
READOUT
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo
Phase 3 · Cardiovascular Risk, Acute Myocardial Infarction (AMI) |
NVO NOVO NORDISK A S | Ziltivekimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-12-14 in 4mo
ESTIMATED |
READOUT
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help P
Phase 2 · Overweight, Obesity |
NVO NOVO NORDISK A S | NNC0662-0419 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|